

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

VOLUNTARY ANNOUNCEMENT

M701 RECEIVES IND APPROVAL FROM FDA

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the latest business updates of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on January 31, 2026, the Investigational New Drug (“**IND**”) application for the Recombinant anti-epithelial cell adhesion molecule (“**EpCAM**”) and anti-cluster of differentiation 3 (“**CD3**”) human-mouse chimeric bispecific antibody (“**M701**”) has been approved by the U.S. Food and Drug Administration (“**FDA**”) for clinical trials. This milestone advances the international clinical development of M701 for malignant pleural effusion (“**MPE**”), bringing new therapeutic options to patients worldwide.

MPE is a common and severe complication of malignant tumors, particularly in advanced lung and breast cancer patients. Current treatments remain largely palliative, highlighting an urgent unmet clinical need. M701 targets EpCAM, a highly expressed antigen on malignant cells in epithelial-derived MPE, and CD3 to activate anti-tumor immunity, enabling synergistic precision therapy.

The approved trial is an open-label, multicenter, phase Ib/II study evaluating the safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of intrapleurally administered M701 in patients with MPE caused by advanced epithelial tumors.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that M701 will ultimately be successfully developed and marketed. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei
Chairman of the Board,
Executive Director and Chief Executive Officer

Wuhan, PRC, February 3, 2026

As of the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive Directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive Directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.